首頁 > 市場調查報告書 > 製藥

消化器

市場調查報告書

商品編碼

1274360

短腸綜合徵全球市場研究報告——2023-2030 年行業分析、規模、份額、增長、趨勢和預測

Global Short Bowel Syndrome Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年05月01日 | 出版商:

Value Market Research | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球對短腸綜合徵市場的需求將從 2022 年的 8.4112 億美元增長到 2030 年的近 55.2245 億美元，在 2023-2030 研究期間的複合年增長率為 26.52%。預計將達到

短腸綜合徵 (SBS) 是一種疾病，其中小腸或小腸的一部分通過手術切除或出現功能障礙，從而導致營養不良和腹瀉。小腸負責從食物中吸收營養，如果缺少任何一個部分，就無法吸收足夠的身體所需的營養。 SBS 可由克羅恩病、癌症和小腸損傷等疾病引起。 SBS 的症狀包括營養不良、腹瀉、腹痛和體重減輕。在嚴重的情況下，可能需要腸外營養（腸外營養）來維持健康。

市場動態：

由於克羅恩病和癌症等導致腸切除的疾病患病率增加等因素，短腸綜合徵的發病率正在增加。這推動了對 SBS 藥物的需求。新手術技術的發展以及新藥和設備的引進正在推動 SBS 市場的增長。這些進展改善了 SBS 患者的預後和生活質量。醫療保健專業人員和公眾對短腸綜合徵的認識不斷提高，這推動了對 SBS 治療的需求。這種認識導致了 SBS 的早期診斷和更有效的治療。政府和私人機構增加對 SBS 研究的投資正在推動 SBS 市場的增長。這項投資導致了新的、更有效的 SBS 治療方法的開發。對於 SBS 的有效治療，仍然存在大量未滿足的醫療需求。這推動了對新的和改進的 SBS 處理的需求，預計這將繼續推動 SBS 市場的增長。

這份研究報告解釋了波特的五力模型、市場吸引力分析和價值鏈分析。這些工具可幫助您清楚地了解您的行業結構並評估您在全球範圍內的競爭吸引力。此外，這些工具還對全球短腸綜合症市場的每個細分市場進行了全面評估。短腸綜合徵行業的發展和趨勢為這項研究提供了一種整體方法。

市場細分：

短腸綜合徵市場細分提供按國家和地區劃分的詳細數據，以幫助確定產品和服務的目標受眾和未來商機。

按產品

胰高血糖素樣□ (GLP2)
成長和諧
谷氨□胺
其他

按分佈

醫院藥房
零售藥房
在線藥店

按地區分析：

本節涵蓋區域展望，重點介紹北美、歐洲、亞太地區、拉丁美洲、中東和非洲短腸綜合症市場當前和未來的需求。此外，我們還關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的綜合概況和全球競爭格局的詳細視圖。短腸綜合徵市場的主要參與者是武田製藥有限公司、默克公司、Zealand Pharma A/S、OxThera、VectivBio AG、9 Meters Biopharma Inc、Nutrinia Ltd、Hanmi Pharm Co Ltd、Pharmascience Inc。競爭格局，包括各種戰略發展，如戰略併購、未來能力、合作夥伴關係、財務概覽、合作、新產品開發和新產品發布。

如果您有定制要求，請聯繫我們。我們的研究團隊可以根據您的需要提供定制報告。

內容

第一章前言

本報告的內容
- 目的
- 目標受眾
- 獨特的銷售主張 (USP) 及其提供的內容
調查範圍
調查方法
- 市場調研過程
- 市場研究方法

第 2 章執行摘要

市場亮點
全球市場概況

第 3 章短腸綜合症 - 行業分析

簡介 - 市場動態
市場驅動力
市場製約因素
市場機會
行業趨勢
波特的五力分析
市場吸引力分析
- 按產品分類的市場吸引力分析
- 市場吸引力分析：按分佈
- 市場吸引力分析：按地區

第四章價值鏈分析

價值鏈分析
原材料分析
- 原材料清單
- 原材料製造商列表
- 主要原材料價格走勢
潛在買家名單
營銷渠道
- 直接營銷
- 間接營銷
- 營銷渠道趨勢

第 5 章 COVID-19 爆發的影響分析

第 6 章全球短腸綜合症產品市場分析

產品概覽
實際數據和預測數據
按產品分析
胰高血糖素樣□ (GLP2)
成長和諧
谷氨□胺
其他

第 7 章全球短腸綜合徵市場分佈分析

分佈概覽
過去和未來的數據
分佈分析
醫院藥房
零售藥房
在線藥店

第 8 章全球短腸綜合症市場分析：按地區

區域展望
簡介
北美銷售分析
- 概覽、歷史和預測銷售分析
- 北美各部門的銷售分析
- 北美銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測銷售分析
- 按細分市場進行的歐洲銷售分析
- 按國家/地區劃分的歐洲銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 意大利銷售分析
- 俄羅斯銷售分析
- 其他歐洲銷售分析
亞太地區銷售分析
- 概覽、歷史和未來銷售分析
- 亞太地區各部門的銷售分析
- 亞太國家/地區銷售分析
- 在中國的銷售分析
- 印度銷售分析
- 日本的銷售分析
- 韓國銷售分析
- 澳大利亞銷售分析
- 其他亞太地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和未來銷售分析
- 拉丁美洲各部門的銷售分析
- 拉丁美洲國家/地區的銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利的銷售分析
- 其他拉丁美洲銷售分析
中東和非洲銷售分析
- 概覽、歷史和未來銷售分析
- 中東/非洲地區的銷售分析
- 中東和非洲國家/地區的銷售分析
- 沙特阿拉伯銷售分析
- 阿聯酋銷售分析
- 以色列銷售分析
- 南非銷售分析
- 其他中東和非洲銷售分析

第 9 章短腸綜合症公司的競爭格局

短腸綜合徵市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第十章公司簡介

頂級公司的市場份額分析
市場集中度
武田製藥有限公司
- 公司簡介
- 企業收入
- 產品介紹
- 近期發展狀況
默克公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
Zealand Pharma A/S
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
OxThera
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
Vectiv 生物公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
9 米生物製藥公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
Nutrinia 有限公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
韓美製藥有限公司
- 公司簡介
- 企業收入
- 產品信息
- 近期發展狀況
Pharmascience Inc.
- 公司簡介
- 企業收入
- 產品信息
- 近期趨勢

注意：公司簡介中的財務細節和近期發展基於可用信息，可能不包括私營公司。

簡介目錄圖表

Product Code: VMR112110467

The global demand for Short Bowel Syndrome Market is presumed to reach the market size of nearly USD 5522.45 MN by 2030 from USD 841.12 MN in 2022 with a CAGR of 26.52% under the study period 2023 - 2030.

Short Bowel Syndrome or SBS is a condition in which the small intestine or its portion is surgically removed or is not functioning properly, causing malnutrition and diarrhoea. The small intestine is the body part responsible for absorbing nutrients from food, and when a portion of it is missing, the body is unable to absorb enough nutrients to meet its needs. SBS can result due to conditions including Crohn's disease, cancer, and injury to the small intestine. Symptoms of SBS may include malnutrition, diarrhoea, abdominal pain, and weight loss. In severe cases, patients may require intravenous nutrition (known as parenteral nutrition) to maintain their health.

Market Dynamics:

The incidence of Short Bowel Syndrome is increasing due to factors such as the increasing prevalence of conditions that lead to bowel resection, such as Crohn's disease and cancer. This is driving the demand for SBS treatments. Development of new surgical techniques and the introduction of new drugs and devices are driving the growth of the SBS market. These advances are leading to better patient outcomes and improved quality of life for SBS patients. The growing awareness about Short Bowel Syndrome, both among healthcare professionals and the general public, is driving the demand for SBS treatments. This awareness is leading to earlier diagnosis and more effective treatment of SBS. Increased investment in SBS research, both by the government and private organizations, is driving the growth of the SBS market. This investment is leading to the development of new, more effective SBS treatments. There is a significant medical need which has not been met for effective treatments for SBS. This is driving the demand for new and improved SBS treatments and is expected to continue to drive the growth of the SBS market in the future.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of short bowel syndrome. The growth and trends of short bowel syndrome industry provide a holistic approach to this study.

Market Segmentation:

This section of the short bowel syndrome market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Glucagon-Like Peptide (GLP2)
Growth Harmone
Glutamine
Others

By Distribution

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Short Bowel Syndrome market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the short bowel syndrome market include Takeda Pharmaceutical Company Limited, Merck KGaA, Zealand Pharma A/S, OxThera, VectivBio AG, 9 Meters Biopharma Inc, Nutrinia Ltd., Hanmi Pharm Co Ltd, Pharmascience Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . SHORT BOWEL SYNDROME - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Distribution
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY PRODUCT

6.1 Overview by Product
6.2 Historical and Forecast Data
6.3 Analysis by Product
6.4 Glucagon-like Peptide (GLP2) Historic and Forecast Sales by Regions
6.5 Growth Harmone Historic and Forecast Sales by Regions
6.6 Glutamine Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY DISTRIBUTION

7.1 Overview by Distribution
7.2 Historical and Forecast Data
7.3 Analysis by Distribution
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL SHORT BOWEL SYNDROME MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE SHORT BOWEL SYNDROME COMPANIES

9.1. Short Bowel Syndrome Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF SHORT BOWEL SYNDROME INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Takeda Pharmaceutical Company Limited
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Merck KGaA
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Zealand Pharma A/S
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. OxThera
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. VectivBio AG
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. 9 Meters Biopharma Inc
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Nutrinia Ltd.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Hanmi Pharm Co Ltd
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Pharmascience Inc
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

簡介目錄圖表